Fig. 5From: Identification and validation of an individualized metabolic prognostic signature for predicting the biochemical recurrence of prostate cancer based on the immune microenvironmentRisk score analysis of the prognostic signature based on the GSE70769 and entire TCGA cohorts. A Kaplan–Meier survival curve analysis of BCRs between the high- and low-risk groups in the GSE70769 cohort. B 1-year, 3-year, and 5-year ROC curves of PCa patients in the GSE70769 cohort. C Risk score and survival status of each PCa patient in the GSE70769 cohort. D Heatmap of prognostic MTGs expression based on the risk score and clinical characteristics in the GSE70769 cohort. E Kaplan–Meier survival curve analysis of BCRs between the high- and low-risk groups in the entire TCGA cohort. F 1-year, 3-year, and 5-year ROC curves of PCa patients in the entire TCGA cohort. G Risk score and survival status of each PCa patient in the entire TCGA cohort. H Heatmap of prognostic MTGs expression based on the risk score and clinical characteristics in the entire TCGA cohortBack to article page